Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	30.98B
Revenue (ttm)	3.34B
Net Income (ttm)	939.58M
Shares Out	408.19M
EPS (ttm)	2.31
PE Ratio	32.86
Forward PE	22.78
Dividend	0.62 (0.82%)
Ex-Dividend Date	May 9, 2025

Volume	2,623,151
Average Volume	2,055,231
Open	76.52
Previous Close	76.18
Day's Range	74.81 - 76.80
52-Week Range	67.96 - 93.52
Beta	-0.11
RSI	34.12
Earnings Date	Mar 27, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.